Intarcia Therapeutics, Inc. announced the enrollment of the first patients in FREEDOM-1, the first of four planned Phase 3 clinical trials studying the safety and efficacy of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes (T2D). Intarcia is conducting the FREEDOM clinical program with strategic partner Quintiles, Inc. who will be responsible for the global implementation of all four trials. This collaboration, along with strategic input from a world-class group of renowned diabetes experts, is designed to achieve the standards of quality, safety and operational excellence.

Intarcia Therapeutics, Inc. announced the appointment of Owen Hughes, Jr., to the position of Chief Business Officer and Head of Corporate Development. Mr. Hughes joins Intarcia from Brookside Capital, where he served as a Director, co-managing all public and private healthcare investments. In his new position, Mr. Hughes will report directly to Intarcia Chairman, President and CEO Kurt Graves.

Intarcia Therapeutics, Inc. Presents at The BIOCOM 3rd Annual Global Life Science Partnering Conference, Feb-28-2013 08:30 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Kurt C. Graves, Executive Chairman, Chief Executive Officer and President.